<code id='9AF78C1E93'></code><style id='9AF78C1E93'></style>
    • <acronym id='9AF78C1E93'></acronym>
      <center id='9AF78C1E93'><center id='9AF78C1E93'><tfoot id='9AF78C1E93'></tfoot></center><abbr id='9AF78C1E93'><dir id='9AF78C1E93'><tfoot id='9AF78C1E93'></tfoot><noframes id='9AF78C1E93'>

    • <optgroup id='9AF78C1E93'><strike id='9AF78C1E93'><sup id='9AF78C1E93'></sup></strike><code id='9AF78C1E93'></code></optgroup>
        1. <b id='9AF78C1E93'><label id='9AF78C1E93'><select id='9AF78C1E93'><dt id='9AF78C1E93'><span id='9AF78C1E93'></span></dt></select></label></b><u id='9AF78C1E93'></u>
          <i id='9AF78C1E93'><strike id='9AF78C1E93'><tt id='9AF78C1E93'><pre id='9AF78C1E93'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:63355
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more
          Biotech execs pursue obesity drug boom: ‘It’s the early innings’
          Biotech execs pursue obesity drug boom: ‘It’s the early innings’

          ElaineChenofSTAT,upperleft,talkedaboutobesitydrugswith,clockwise,RaymondStevenofStructureTherapeutic

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          AstraZeneca stays mum on Medicare drug pricing negotiations

          AstraZenecaCEOPascalSoriotJacquelynMartin/APLONDON—Medicare’sfirst-everdrugpricingnegotiationsareoff